Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study

BCC Clinical Trial

Official title:
A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study

Status Completed

Clinical Trial Summary

This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC. Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned surgical excision of the lesion.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02007317
Study type	Interventional
Source	Oshadi Drug Administration
Contact
Status	Completed
Phase	Phase 2
Start date	November 2013
Completion date	March 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04552990` - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma	Phase 2
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Recruiting	`NCT06150144` - The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma	Phase 3
Completed	`NCT04918381` - CellFX Treat & Resect Low-Risk BCC Feasibility Study	N/A
Recruiting	`NCT06279143` - The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes